Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
First Claim
Patent Images
1. A method for treating progressive decline in heart muscle function due to myocardial ischemia, which comprises(a) determining eligibility of the subject by clinically evaluating the heart muscle function;
- (b) administering parenterally to the subject through a catheter on a first infusion date a sterile pharmaceutical composition comprising a therapeutic amount of a chemotactic hematopoietic stem cell product comprising;
(i) a nonexpanded, isolated population of autologous mononuclear cells enriched for CD34+ cells, which further contains a subpopulation of potent CD34+/CXCR-4+ cells that have CXCR-4-mediated chemotactic activity; and
(ii) a stabilizing amount of serum, wherein the stabilizing amount of serum is at least 10% (v/v) and is effective to retain the CXCR-4-mediated chemotactic activity and hematopoietic colony forming activity of the subpopulation of CD34+/CXCR-4+ cells;
the composition being characterized as having the following properties for at least 24 hours following acquisition of the mononuclear cells when tested in vitro after passage through the catheter;
(1) at least 70% of the cells in the composition are CD34+ cells,(2) the subpopulation of CD34+/CXCR-4+ cells have CXCR-4-mediated chemotactic activity move in response to SDF-1,(3) at least 70% of the cells in the composition are viable, and(4) can form hematopoietic colonies in vitro;
wherein the therapeutic amount of the chemotactic hematopoietic stem cell product comprises at least 10 million isolated CD34+ cells comprising at least 0.5×
106 potent CD34+/CXCR-4+ cells that have CXCR-4-mediated chemotactic activity and that move in response to SDF-1; and
(c) repeating steps (a) through (b) on at least one or more infusion dates during the subject'"'"'s lifetime;
thereby treating the progressive decline in heart muscle function due to myocardial ischemia by;
improving myocardial perfusion of the myocardium and;
reducing apoptosis of existing cardiomyocytes in the myocardium, thereby preserving their function.
2 Assignments
0 Petitions
Accused Products
Abstract
The described invention provides methods and regimens for treating adverse consequences of a persistent and progressive myocardial injury-due to a vascular insufficiency that occurs early or late in a subject in need thereof, and progressive myocardial injury-preventing compositions that contain a chemotactic hematopoietic stem cell product, and, optionally, an additional active agent.
66 Citations
29 Claims
-
1. A method for treating progressive decline in heart muscle function due to myocardial ischemia, which comprises
(a) determining eligibility of the subject by clinically evaluating the heart muscle function; -
(b) administering parenterally to the subject through a catheter on a first infusion date a sterile pharmaceutical composition comprising a therapeutic amount of a chemotactic hematopoietic stem cell product comprising; (i) a nonexpanded, isolated population of autologous mononuclear cells enriched for CD34+ cells, which further contains a subpopulation of potent CD34+/CXCR-4+ cells that have CXCR-4-mediated chemotactic activity; and (ii) a stabilizing amount of serum, wherein the stabilizing amount of serum is at least 10% (v/v) and is effective to retain the CXCR-4-mediated chemotactic activity and hematopoietic colony forming activity of the subpopulation of CD34+/CXCR-4+ cells; the composition being characterized as having the following properties for at least 24 hours following acquisition of the mononuclear cells when tested in vitro after passage through the catheter; (1) at least 70% of the cells in the composition are CD34+ cells, (2) the subpopulation of CD34+/CXCR-4+ cells have CXCR-4-mediated chemotactic activity move in response to SDF-1, (3) at least 70% of the cells in the composition are viable, and (4) can form hematopoietic colonies in vitro; wherein the therapeutic amount of the chemotactic hematopoietic stem cell product comprises at least 10 million isolated CD34+ cells comprising at least 0.5×
106 potent CD34+/CXCR-4+ cells that have CXCR-4-mediated chemotactic activity and that move in response to SDF-1; and(c) repeating steps (a) through (b) on at least one or more infusion dates during the subject'"'"'s lifetime; thereby treating the progressive decline in heart muscle function due to myocardial ischemia by; improving myocardial perfusion of the myocardium and; reducing apoptosis of existing cardiomyocytes in the myocardium, thereby preserving their function. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)
-
Specification